This is a single center, open label, phase II study which will evaluate the use of DOPASCAN in diagnosing and monitoring progression of Parkinson's disease. A second study objective was to assess the binding potential of DOPASCAN in the brain of the two study groups, using SPECT imaging.
Showing the most recent 10 out of 869 publications